Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies

Asthana, Shalini; Gupta, Pramod; Jaiswal, Anil K.; Dube, Anuradha; Chourasia, Manish K.

doi:10.1007/s11095-015-1651-0

Cited by 20 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zia et al (2015) showed that killing of intracellular C. albicans after treatment with amphotericin B polyglutamic acid nanoparticles was higher than with Ambisome® (Zia et al, 2015). Amphotericin B is also used for the treatment of infections caused by Leishmania spp., which is an intracellular parasite, so that intense investigation has been done in order to enhance drug antiparasitic effects throughout nanostruturation (Asthana et al, 2015; Jain et al, 2015; Bose et al, 2016). …”

Section: Nanopreparations For Polyenesmentioning

confidence: 99%

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Souza

Amaral

2017

Front. Microbiol.

View full text Add to dashboard Cite

Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising results in vitro and in vivo. In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis.

show abstract

Section: Nanopreparations For Polyenesmentioning

confidence: 99%

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Souza

Amaral

2017

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The same team improved the targeting capability of chitosan, using mannosylated chitosan (Mnos-CS) copolymer, subsequently formulated in a nanocapsule system (MnosCNc) for the delivery of AmpB. 121 Using nanocapsules, DL of 9%-10% (w/w) was obtained. In vivo results showed that more drug was delivered by mannosylated nanocapsules than by CNC or plain AmpB in both liver and spleen.…”

mentioning

confidence: 99%

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Bruni¹,

Stella²,

Giraudo³

et al. 2017

IJN

View full text Add to dashboard Cite

Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania , which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.

show abstract

“…Chemotherapy for VL is based on the use of antimony. However, the emergence of resistance has transformed medical management to the use of amphotericin B (AmB) for VL treatment [2,3]. Notably, targeted intracellular delivery of AmB has now emerged as a first-line medical strategy to facilitate pathogen clearance.…”

mentioning

confidence: 99%

“…Notably, targeted intracellular delivery of AmB has now emerged as a first-line medical strategy to facilitate pathogen clearance. The development of improved drug delivery formulations that include nanotechnology-based targeted therapeutics that target infected cells and tissues could improve treatment outcomes [3,4]. …”

mentioning

confidence: 99%

“…Specifically, mannosylation of TC polymer (MTC) is believed to be an appealing strategy for targeted intracellular MP delivery of AmB as it would not only aid in parasite clearance but also help reduce the dosing volume and frequency. To date, there is only limited research that has been conducted to investigate the potential of mannose-anchored thiolated nanocarriers for VL and linked parasitic disease therapy [2,3,14]. In this study, improved mannose-anchored TC (MTC) nanocarriers were developed to facilitate stability, biocompatibility, controlled release and cell uptake by macrophages for antileishmanial therapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Development of mannose-anchored Thiolated Amphotericin B Nanocarriers for Treatment of Visceral Leishmaniasis

Shahnaz

Edagwa

McMillan

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim:Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized.Materials & methods:A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities.Results:MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug.Conclusion:These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.

show abstract

Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies

Cited by 20 publications

References 25 publications

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Development of mannose-anchored Thiolated Amphotericin B Nanocarriers for Treatment of Visceral Leishmaniasis

Contact Info

Product

Resources

About